Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome

Pavel Májek*, Zuzana Riedelová-Reicheltová, Jiří Suttnar, Klára Pečánková, Jaroslav Čermák and Jan E Dyr

Abstract

**Background:** Refractory anemia and refractory anemia with ringed sideroblasts are two myelodysplastic syndrome (MDS) subgroups linked with anemia. MDS is a group of heterogeneous oncohematological bone marrow disorders characterized by ineffective hematopoiesis, blood cytopenias, and progression of the disease toward acute myeloid leukemia. The aim of this study was to search for plasma proteome changes in MDS patients with refractory anemia and refractory anemia with ringed sideroblasts.

**Results:** A total of 26 patient and healthy donor plasma samples were depleted of fourteen high-abundant plasma proteins, separated with 2D electrophoresis, and statistically processed with Progenesis SameSpots software. 55 significantly differing spots were observed and corresponded to 39 different proteins identified by nanoLC-MS/MS. Changes in the fragments of the inter-alpha-trypsin inhibitor heavy chain H4 protein were observed. Using mass spectrometry-based relative label-free quantification of tryptic peptides, there were differences in alpha-2-HS-glycoprotein peptides, while no differences were observed between the control and patient sample groups for retinol-binding protein 4 peptides.

**Conclusions:** This study describes plasma proteome changes associated with MDS patients with refractory anemia and refractory anemia with ringed sideroblasts. Changes observed in the inter-alpha-trypsin inhibitor heavy chain H4 fragments were in agreement with our previous studies of other MDS subgroups: refractory cytopenia with multilineage dysplasia and refractory anemia with excess blasts subtype 1. Mass spectrometry-based relative quantification of retinol-binding protein 4 peptides has shown that there are differences in the modification of this protein between refractory anemia with excess blasts subtype 1 patients and MDS patients with refractory anemia and refractory anemia with ringed sideroblasts. Alpha-2-HS-glycoprotein seems to be a new potential MDS biomarker candidate.

**Keywords:** Myelodysplastic syndrome, Refractory anemia, Refractory anemia with ringed sideroblasts, Proteome changes, Alpha-2-HS-glycoprotein

* Correspondence: pavel.majek@uhkt.cz
Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20, Prague 2, Czech Republic

© 2013 Májek et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
Anemia, one of the most common blood disorders, is usually caused by the decrease of red blood cells. Thus, the oxygen-carrying capacity of the blood is decreased, and anemic patients consequently feel tired and suffer from other consequences of hypoxia. As one of the most common causes of anemia is bleeding, an iron deficiency, underproduction, or excessive destruction of red blood cells also occur.

Refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS) are two myelodysplastic syndrome (MDS) subgroups linked with anemia, according to the World Health Organization (WHO) classification of MDS [1]. Both RA and RARS are characterized by dysplasia limited only to the erythroid lineage; by less than 5% of blasts located in the bone marrow, and with limited response of the anemia to treatment.

Very little is known about plasma protein alterations occurring in myelodysplastic syndrome. Even though there are several proteomic studies dealing with MDS [2-4], including our previous studies of refractory cytopenia with multilineage dysplasia (RCMD) [5] and refractory anemia with excess blasts subtype 1 (RAEB-1) [6], there is still a lack of data from different MDS subgroups that would enable comparison of these subgroups. The possibility to find proteins that change either in general in MDS, or just within specific subgroups, could benefit our knowledge of the molecular mechanisms and (patho)physiology of MDS, and these results might thus influence the diagnosis, treatment, and prognosis of the disease.

Although there are many proteomic methods and techniques (e.g. chromatography, mass spectrometry, protein biosensors [7-9]) that offer the possibility to look for protein alterations in biologic samples, 2-D electrophoresis is usually the first choice despite some disadvantages. Nevertheless, there is no 'all purpose' proteomic method, and each one has its own limitations. The preference for 2-D electrophoresis in the first level of proteome exploration results from the possibility to observe within the analysis, not only proteins which change in the concentration, but also those posttranslationally modified. It has been shown that not only plasma protein levels change, but also the presence of specific protein isoforms, which may be of interest [10].

The aim of this proteomic study has been to explore the plasma proteome of MDS patients with refractory anemia and refractory anemia with ringed sideroblasts, and to search for possible protein alterations in comparison with healthy controls.

Methods
A total of 10 patient plasma samples (7 RA and 3 RARS patient samples were included in the patient group further denoted as RA-RARS) and 16 healthy controls have been investigated in this proteomic study. The diagnosis of RA and RARS was established according to the WHO classification criteria [1]. The age of the patients ranged from 50 to 89 years, and there were 4 males (40%). Sex-matched, healthy control donor age ranged from 21 to 35, and there were 6 males (38%). All individuals tested agreed to participate in the study on the basis of an informed consent. All samples were obtained and analyzed in accordance with the Ethical Committee regulations of the Institute of Hematology and Blood Transfusion.

150 μl of diluted plasma (1:3 in MARS depletion buffer) was used to deplete high-abundant plasma proteins (MARS Hu-14 column; Agilent, Santa Clara, CA, USA). This corresponded to the volume of 37.5 μl of undiluted plasma used for each sample in this study. Blood sample collection, plasma depletion, and sample processing and storage were described in detail in our previously published literature [5,6]. 2D electrophoresis, image analysis, protein in-gel digestion, and mass spectrometry identification of proteins were also performed as described in previous literature [10-12]. Briefly, isoelectric focusing (IPG strips pI 4–7, 7.7 cm) was followed by SDS-PAGE (8 x 10 cm, 10% resolving gel, 3.75% stacking gel, 30 mA/gel), gels were scanned and processed with Progenesis SameSpots software (Nonlinear Dynamics, Newcastle upon Tyne, UK) that computed fold and p-values of all spots using one way ANOVA analysis, and Principal Component Analysis (PCA) was performed. PCA was performed using only the spots of statistical significance (based on 2D SDS-PAGE) employed for protein identification. PCA was used to assess whether grouping of patients and healthy controls based on the 2D SDS-PAGE results reflects their stratification using clinical diagnosis. No technical replicates were used for 2D SDS-PAGE (non-pooled individual samples of patients and donors were used only). MS/MS mass spectrometry (HCT ultra ion-trap mass spectrometer with nanoelectrospray ionization; Bruker Daltonics, Bremen, Germany) coupled to a nanoLC system (UltiMate 3000; Dionex, CA, USA) was used to perform MS analysis. Mascot (Matrix Science, London, UK) was used for database searching (Swiss-Prot). To eliminate peptide carry-over between HPLC separations, cleaning runs were performed before and after each sample run. Two unique peptides (with a higher Mascot score than the minimum for identification, p < 0.05) were necessary to successfully identify a protein.

Relative label-free protein quantification was used to compare tryptic peptide levels of alpha-2-HS-glycoprotein (A2HSG) and retinol-binding protein 4 (RBP4) in the patient and control groups. Plasma proteins were digested using modified protocols of acetonitrile precipitation of plasma proteins and trypsin digestion, as described by Kay et al. [13]. Briefly, to the 50 μl of sample plasma, 100 μl of water, and 225 μl of acetonitrile were added, and then
sonicated twice for 10 min with vortexing between sonica-
tions. After centrifugation (10 min, 12000 × g) 300 µl of
supernatant were transferred into a new Eppendorf tube
and completely dried. Pellets were then resuspended in
40 µl of 0.1 M NH₄HCO₃, 5 µl of 0.1 M DTT were added,
and the samples were incubated for 1 hr at 60°C. After the
samples cooled, 5 µl of 0.1 M iodoacetamide were added,
and the samples were incubated at room temperature in
the dark for 30 min. Trypsin digestion was started by
adding 4 µl of trypsin (200 µg/mL) in 50 mM acetic acid
digested at 37°C overnight. The reaction was stopped
with the addition of 6.5 µl of 1% formic acid. Samples were
centrifuged (10 min, 12000 × g), filtered, and 20 µl of each
sample was loaded for LC-MS/MS analysis. Two A2HSG
peptides were monitored: HTFMGVVSLGSPSGEVSHPR
with precursor ion 694.7 m/z (charge 3+) and product ion
1109.5 m/z (y11); and EHAVEGDCDFQLLK with preci-
sor ion 830.9 m/z (2+) and product ion 1095.5 m/z (y9).
Peptides, precursor, and product ions were chosen on the
basis of MS/MS analysis (previous protein identification).
RBP4 peptides were the same as monitored in our pre-
vious publication describing plasma proteome changes
in RAEB-1 [6]: FSGTWYAMAK with precursor ion
589.3 m/z (2+) and product ion 785.3 m/z (y6); and
YWGVASFLQK with precursor ion 599.9 m/z (2+) and
product ion 849.5 m/z (y8). The nanoLC-MS/MS
system was the same as described above, but using a
60 min 0-70% acetonitrile non-linear gradient, with a
precursor selection window width of 2 Da. Extracted
ion chromatograms of the product ions were generated
with an ion m/z width of ± 0.5 Da, and peak areas were
calculated after automatic integration using DataAnalysis
software (version 4.0; Bruker). Each sample was measured
twice, and a t-test was used for statistical analysis. All
sample results were validated according to MS/MS spectra
and retention times [14]. Blank runs were performed
before and after each sample run to eliminate peptide
carry-over.

Western blotting was performed as described previously
[10]. Briefly, proteins were transferred from a gel to a
PVDF membrane (10 V constant voltage for 1 hr), the
membrane was then incubated with a blocking buffer
(3% BSA in PBS) at 4°C overnight, rinsed, and incubated
with an anti-ITIH4 primary antibody (1:2,000 dilution
(Ananova, Taipei, Taiwan) or an anti-RBP4 primary
antibody (1:2,000 dilution) (Abcam, Cambridge, UK), at
30°C for 45 min. Then the membrane was incubated with
the secondary antibody, rabbit anti-mouse IgG
antibody conjugated with peroxidase (for ITIH4 detec-
tion, 1:60,000 dilution) (Sigma-Aldrich, Prague, Czech
Republic) or goat polyclonal anti-rabbit IgG antibody
conjugated with peroxidase (for RBP4 detection, (for RBP4
detection, 1:10,000 dilution) (Abcam, Cambridge, UK), at
30°C for 45 min. After rinsing, a chemiluminescent substrate
(SuperSignal West Pico; Thermo Scientific, Waltham,
MA, USA) was added to the membrane for 5 min; and
an appropriate film exposure (Amersham Hyperfilm
ECL; GE Life Sciences, Piscataway, NJ, USA) was
performed. In total, 6 patient (3 RA and 3 RARS) and 6
sex-matched control samples were used for western
blotting; pooled patient and control samples were used
in addition.

Figure 1 Positions of significantly differing spots on a 2D gel. Positions of all 55 spots that were found to differ significantly (p < 0.05) when
RA-RARS patients were compared to healthy controls. A 2D gel of a patient sample was used as the illustrative gel to display spot positions.
The alpha-2-HS glycoprotein plasma level was measured using a commercial ELISA kit (Abcam, Cambridge, UK). Sex-matched samples were measured according to manufacturer instructions; results were expressed as means ± standard deviations. An unpaired t-test was used for the comparison of plasma levels between RA-RARS and patient groups.

**Results**

2-DE gels of all samples were prepared for the experiment, and scanned 2-DE gel images were divided into patient (n = 10) and control (n = 16) groups. Comparing these two groups we found 55 unique spots that differed significantly (p < 0.05) in normalized volumes (Figure 1). An example of four differing spots is shown in Figure 2. Proteins in 49 spots were identified, which corresponded to 39 different proteins. The list of all spots, including ANOVA p-values, their multiplication (fold value), protein identification with the number of identified peptides (unique peptides above the identity threshold score), protein accession number (Swiss-Prot), and the sequence coverage, is summarized in Table S1 (See Additional file 1: Table S1).

Principal Component Analysis (PCA) was performed making use of Progenesis SameSpots software employing only the spots of statistical significance (based on 2D electrophoresis). PCA showed an obvious separation of all samples (2-DE gels) into two aggregates corresponding to the patient (blue dots) and the control (pink dots) groups, respectively (Figure 3).

In several spots (4, 9, 11, 12, 20, 27, 28, 41, 52, and 55), fragments of inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) was observed. The molecular weights of the spots, as estimated using 2-DE, corresponded to both 35 kDa ITIH4 (spots 9, 11, 12, 20, 27, 28, and 41) and 70 kDa ITIH4 (spots 4, 52, and 55) fragments. Moreover, when comparing the sequences of ITIH4 identified peptides (using MS/MS) in all spots with the observed fragmentation, these peptides corresponded to both 35 and 70 kDa ITIH4 processed proteins. Significantly differing spots containing uncleaved ITIH4 were not observed. ITIH4 expression was assessed by western blot analysis; a single band of more than 100 kDa of molecular weight

**Figure 2** An example of four differing spots. This figure represents an example of four differing spots (4, 9, 11 and 20). Expression profiles with the logarithms of spot normalized volumes and their standard deviations for RA-RARS patient and healthy control groups are shown.
was observed (Figure 4). This band corresponded to the uncleaved ITIH4, and no difference in ITIH4 expression between the patient group (n = 6) and the control group (n = 6) was observed. Using a monoclonal anti-ITIH4 antibody capable of detecting uncleaved ITIH4 and 70 kDa ITIH4 fragment, we did not observe the 70 kDa ITIH4 fragment (the antibody did not act against the 35 kDa ITIH4 fragments).

RBP4 expression was assessed by western blot analysis as described above; the same patient (n = 6) and sex-matched control (n = 6) samples as for ITIH4 western blot analysis were used. No difference was observed between patient RA-RARS and healthy control groups when comparing individual or pooled samples (Figure 4).

The data obtained using 2-DE cannot provide information on the cause of the observed change – plasma level change or posttranslational modification (PTM). Comparisons of different peptides of the same protein in two different groups (patient and control) using relative quantification may provide additional information – at least two unique fold change values in two different peptides can prove the presence of PTM(s), which would have influenced the results observed using 2-DE (based on spot volume changes). As co-identification of other proteins within a spot impairs data interpretation, proteins with unique identifications in their spots, together with satisfactory p-values, were considered for relative quantification. Moreover, we focused on proteins possibly related to MDS and its pathophysiology. Two proteins satisfied these criteria, and relative label-free protein quantification was used to compare tryptic peptide levels of alpha-2-HS-glycoprotein (A2HSG) and retinol-binding protein 4 (RBP4) in the patient (n = 10) and control (n = 10) groups. The samples were the same as used for 2-DE, and the control samples were sex-matched with the patient group samples. Quantification of A2HSG showed different fold change values for its peptides; the average peak area value was increased by more than two-fold in the MDS group (2.54-fold, no statistical significance) when compared with the control group for 694.7/1109.5, while there was no obvious difference for 830.9/1095.5 (0.95-fold decrease) in the MDS group when compared to the control group. For RBP4 peptides, there were observed no differences between the control and the patient sample groups for both peptides: 0.92-fold and 1.12-fold difference for 589.3/785.3 and 599.9/849.5, respectively. The results are summarized in Table 1.

The plasma level of A2HSG was measured for all patient RA-RARS samples (n = 10) and sex-matched control samples (n = 10): 471 ± 38 μg/ml (RA-RARS) and 562 ± 28 μg/ml (control). This corresponds to 1.2-fold decrease of A2HSG plasma level in the patient group. The difference was found to be statistically significant (t-test, p = 1.3 × 10^{-5}).

**Discussion**

This paper represents the first report on plasma proteome changes using 2-DE in MDS patients with RA and RARS subgroups of MDS. Both RA and RARS are closely related subgroups of MDS, and according to Malcovati _et al._ [15] are characteristic with a very low risk of transformation into acute myeloid leukemia and good predicted survival. According to WHO Classification-Based Prognostic Scoring System (WPSS) for MDS [15], there are different
risk categories – both RA and RARS belong to the very low risk group. Our previously studied groups RCMD [5] and RAEB-1 [6] belong to low and intermediate risk groups, respectively. Therefore, including this study, there are three different MDS risk groups that can be compared so far, and it is a future task to explore proteome changes in the high risk RAEB-2 subgroup. When the results of all of the three so-far-studied MDS subgroups are compared in general, it is interesting that there is no substantial difference in the number of observed changes; there were 61, 56, and 55 significant changes observed in RCMD, RAEB-1, and RAEB-2, respectively. Despite differences in the number of samples in the studied subgroups, we expected an increase in the number of observed changes in plasma proteome correlating to an increasing WPSS score of the studied subgroups. It seems that it is rather an increase in ‘a depth of changes’ than in the number of changes. Thus, it is important to look for changes in the initial step (selection of candidate proteins); however, it seems probably even more important to profile protein changes (whether caused by protein level changes or PTMs) in different MDS subgroups in the future. Another issue that should be noted is the choice of the control group, which differs in age range when compared to the MDS patient group. Optimally, the control group should match for as many parameters as possible. As MDS usually occurs in elderly patients, the control group should be of similar age range. However, this matching may contribute to other limitations – the primary difficulty is to find healthy individuals of older age who do not suffer from other diseases (diabetes, hypertension etc.) which may significantly affect the obtained results. Further, MDS is not exclusively limited to elderly patients only. Considering that, we decided to compare our patient group with a healthy control group of lower age range to possibly observe all the changes that would occur. Moreover, we used the same characteristic for the control group as in our previous proteomic studies of MDS patients [5,6] to be consistent in the results and their interpretation.

When compared to our previous proteomic studies characterizing changes in the plasma proteome of patients with RCMD [5] and RAEB-1 [6], there is agreement in some results. One of the most evident is the presence of fragmentation of the ITIH4 protein. Normalized volumes of spots containing ITIH4 fragments corresponding to 35 kDa ITIH4 were decreased in RA-RARS, as well as in both the RCMD and RAEB-1 groups, when compared to the control groups. A 70 kDa ITIH4 fragment was identified in the RA-RARS and RCMD groups with the same characteristics of the changes of spot volume (decrease); however, it was only co-identified in spots together with other proteins and thus its interpretation would be speculative. It remains a question whether ITIH4 fragmentation (or modification) could be MDS specific – comparisons of MDS subgroups together with different control groups (non-MDS cytopenias etc.) would be welcome. Even though ITIH4 fragmentation has been found to be potentially associated with MDS [3], it has been also found in other malignant diseases [16,17]. Therefore, ITIH4 fragments could in general be considered as a cancer marker, but not as a marker specific to MDS. Nevertheless, there should be other more specific proteomic data to definitively draw such conclusions; the fragmentation pattern should be elucidated, as well as the possible influence of PTMs. For example, the 70 kDa ITIH4 fragment was not observed in RA-RARS, RAEB-1, or RCMD (using western blot analysis) even though the antibody used should have detected it. This could suggest that the fragmentation did not correspond to that induced by kallikrein (which processes the plasma ITIH4 and cleaves it to produce 35 and 70 kDa fragments). This notion may be supported by the fact that fragments found in proteomic study by Chen et al. [3] using mass spectrometry plasma profiling were smaller than 35 or 70 kDa. Inflammation could be another factor that influences ITIH4 alterations, as this protein is known to belong to the group of acute phase proteins.

A2HSG has been found to be related to several functions – endocytosis, opsonization, or bone tissue formation [18-20]. This protein has been localized in the bone marrow matrix, and is believed to influence bone marrow development and function [21]. It has been also shown that A2HSG is linked to inflammation, and is one of the acute phase proteins, which may be regulated either positively (in some cases) or negatively during an acute phase reaction [22-24]. A2HSG is also supposed to be involved in diabetes [25] and insulin resistance [26], the regulation of protease activity [27], the development of atherosclerosis [28], etc. It has been shown that

---

**Table 1 Relative label-free quantification of proteins**

| Protein   | Peptide sequence       | Precursor ion [m/z] | Precursor charge | Product ion [m/z] | Product ion | fold (MDS/N) |
|-----------|------------------------|---------------------|------------------|-------------------|-------------|--------------|
| A2HSG     | HTPGWLSGSPGVE/SHPR     | 694.7               | +                | 1109.5            | y11         | 2.54         |
| A2HSG     | HAEVGDCEFQLKK          | 830.9               | +                | 1095.5            | y9          | 0.95         |
| RBP4      | FSGTWYAMAK             | 589.3               | +                | 785.3             | y6          | 0.92         |
| RBP4      | YWGASFLQK              | 599.9               | +                | 849.5             | y8          | 1.12         |

A2HSG (alpha-2-HS-glycoprotein), RBP4 (retinol-binding protein 4), no fold value was found to be significantly different.
A2HSG regulates tumor growth in mice and, therefore, it is suspected to be involved in the pathophysiology of malignant diseases [29]. Anti-A2HSG antibodies have been found in the serum of breast cancer patients [30]. In spite of many diseases and processes of which A2HSG is supposed to be involved in, the exact mechanisms of A2HSG function in (patho)physiology are not known. The connection of A2HSG with cytokines, inflammation, and the bone marrow (and its development) could be of interest in relation to MDS. However, it is difficult to speculate on the possible role of A2HSG in MDS, especially when taking into account that plasma levels may be either decreased or increased due to different conditions [31]. In this study, A2HSG has been identified in four spots, with unique identifications in two of them (spots 3 and 29). Normalized volumes of both the spots were decreased (2.3 and 1.4-fold) in the RA-RARS group. This corresponds to the observed decrease of A2HSG plasma level when absolute quantification was performed (fold 1.2); however, this fold value corresponds rather to 1.4-fold value as observed in the spot 29 than to 2.3-fold in the spot 3. The presence of A2HSG in a few spots changing with different fold values indicates PTMs(s); the discrepancy between the changes observed in 2-DE data and absolute quantification further supports this assumption. Finally, relative quantification results showed that while one of the two estimated A2HSG peptides was not altered at all (0.95-fold change), the second peptide was increased more than two-fold in the MDS group (2.54-fold). This also suggests the presence of PTM(s); however, the change was not found to be statistically significant. In a study by Petrik et al. [32], A2HSG was found to be a serum marker of survival in patients with glioblastoma; moreover, A2HSG serum level change was not related to comorbidity and inflammation (it has been shown that a decrease in A2HSG levels correlated with the degree of tumor malignancy). The authors also point out that A2HSG was not a glioblastoma specific marker, as there was correlation with the malignancy of other tumor types. As this protein (the decrease in plasma/serum protein levels) mirrors the degree of malignancy found in different tumor types and we have observed decreases of spot normalized volumes in MDS patients, the future task should be profiling the change (and possible correlation) of A2HSG plasma levels in patients with different MDS subgroups, according to their survival and the degree of malignancy. This was not possible to perform yet, due to the limited number of samples. It is also interesting that the change in A2HSG in the study by Petrik et al. [32] was found in the A2HSG B-chain, while in our study the A-chain and the connecting peptide were identified (both chains are linked by disulfides, whose bonds are disrupted during 2-DE sample analysis; the B-chain Mw is less than 3 kDa, and therefore could not be detected in our study using 2-DE). As Petrik et al. further estimated serum levels using the turbidimetric method and polyclonal antibodies, the decrease in A2HSG serum level should correspond to the whole protein molecule. Nevertheless, the authors also speculated on the possible influence of PTMs (in terms of B-chain and the whole A2HSG molecule); and our study suggests that there could be such a factor (PTM) according to the comparison of 2-DE, absolute and relative quantification results. Another factor that could influence the A2HSG plasma/serum level is proteolytic degradation of the protein; the presence of A2HSG fragments in serum (depending on the protein preparation) has been described in existing literature [22]. However, Petrik et al. [32] has proven that the A2HSG level in serum is stable for at least two weeks at 4°C, including after several freeze-thaw cycles.

Retinol-binding protein 4 (RBP4) is a specific carrier protein for retinol [33]; it is associated with variables related to insulin resistance [34]; is involved in inflammation and related to liver function; and its serum level is reduced in critically ill patients [35]. Using 2-DE, a change (decrease) in RBP4 was also observed in the group of chemosensitive patients with multiple myeloma, which were treated with bortezomib-based regimens, when compared with patients resistant to chemotherapy [36], and also in the sera of epithelial ovarian cancer patients [37]. It has also been shown that an increased ratio of unbound to bound (binding to retinol) RBP4 levels may induce apoptosis in renal and endothelial cells [38]. It is known that retinoids (retinol, etc.) are involved in cell differentiation and in tumor development, probably due to the disruption of retinoid signaling [39]. Some anticancer agents may induce RBP4 expression in vivo [40]. In our previous proteomic study of the RAEB-1 subgroup [6], RBP4 was identified in a spot with a decreased normalized volume in patients with MDS, compared to healthy controls. Relative label-free quantification of RBP4 peptides was performed; the influence of PTM was not proven; and it was speculated that a RBP4 plasma level change was possibly specific for the RAEB-1 subgroup. In this study, RBP4 was uniquely identified in one spot (spot 30) with its normalized volume decreased in the patient group by 1.4-fold. Thus, the results obtained by 2-DE are in accord with the RAEB-1 subgroup. Nevertheless, when results of relative label-free quantification of RBP4 peptides are compared, some differences may be observed. Relative quantification was performed using the same peptides and conditions as in the previously studied RAEB-1 subgroup. Even though there were no differences between the patient and the healthy control groups observed in both subgroups (i.e., no PTM in the monitored peptides was proven), it is remarkable that there was no difference in peptide levels in RA-RARS observed at all (0.92 and 1.12-fold difference between
the patient and control groups), while there was a decrease in the same peptide levels in RAEB-1 (2.33 and 3.25-fold). This strongly indicates an influence of PTM(s) of RBP4 in the RA-RARS subgroup with the position(s) in other (not monitored) peptides. It also suggests that the results observed in the RAEB-1 subgroup were not caused by RBP4 plasma level change only, as it was speculated in the RAEB-1 study [6], but it is likely that there was an influence of both protein modification and level changes. In this study, RBP4 expression estimated by western blot analysis showed no obvious difference. Therefore, western blot analysis supports the notion that RBP4 was influenced by PTM(s). The RBP4 results have shown that although there are almost identical observations using 2-DE, it is necessary to use other methods to ‘see beyond’ as the similar results may be caused by different factors. It has also been shown that mass spectrometry-based relative label-free quantification of peptides may provide additional useful information, in spite of monitoring only a limited number of peptides.

Conclusions
In conclusion, this is the first report on plasma proteome changes, using 2D electrophoresis, in MDS patients with refractory anemia and refractory anemia with ringed sideroblasts. When comparing results to our previous proteomic studies of other MDS subgroups (refractory cytopenia with multilineage dysplasia and refractory anemia with excess blasts subtype 1), there are agreements in some cytopenia with multilineage dysplasia and refractory anemia and refractory anemia with ringed sideroblasts. When comparing results to our previous study of refractory anemia with sideroblasts. When comparing results to our previous study of refractory anemia with sideroblasts, using 2D electrophoresis, in MDS patients with refractory anemia and refractory anemia with ringed sideroblasts.

Additional file

Additional file 1: Table S1. List of spots that differed significantly when RA-RARS patients and healthy controls were compared.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
PM and ZR designed and performed research, analyzed data, and wrote the manuscript. JC diagnosed the patients and collected the samples. KS, JC, and JED designed research and wrote the manuscript. All authors have read and approved the final manuscript.

Acknowledgements
This study was supported by the Czech Science foundation P205/12/G118 and by the project (Ministry of Health, Czech Republic) for conceptual development of research organization (Institute of Hematology and Blood Transfusion).

Received: 26 January 2013 Accepted: 4 April 2013
Published: 8 April 2013

References
1. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
2. Zhong LY, Liu TH, Li YQ, Geng SX, Lu ZS, Weng JY, Wu SJ, Luo CW, Du X: Serum proteomics in patients with RAEB myelodysplastic syndromes. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29:1799-1801.
3. Chen C, Bowen DT, Giagounidis AA, Schlegelberger B, Haase S, Wright EG: Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).

Leukemia 2010, 24:1875-1884.
4. Avado M, Spentzos D, Geering U, Alterovitz G, Meng XY, Gaill F, Giagounidis AA, Klement G, Stekal U, Otu HH, Czabere A, Pfaller WC, Iking-Ikonier C, Shanye M, Ramoni MF, Gattermann N, Haas R, Mittlides CS, Fung ET, Libermann TA: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci U S A 2007, 104:1307-1312.
5. Májek P, Reicheltová Z, Satrnar J, Čermák J, Dyr JE: Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Sci 2011, 9:64.
6. Májek P, Reicheltová Z, Satrnar J, Čermák J, Dyr JE: Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. Proteome Sci 2012, 10:31.
7. Rodríguez-Emmenegger C, Brynda E, Redel T, Houska M, Subr V, Alles AB, Hasan E, Gautrot JE, Huck WT. Polymer brushes showing non-fouling in blood plasma challenge the currently accepted design of protein resistant surfaces. Macromol Rapid Commun 2011, 32:952-957.
8. Rodríguez-Emmenegger C, Brynda E, Redel T, Sedlakova Z, Houska M, Alles AB: Interaction of blood plasma with antifouling surfaces. Langmuir 2009, 25:6328-6333.
9. Redel T, Brynda E, Dyr JE, Houska M: Controlled preparation of thin fibrin films immobilized at solid surfaces. J Biomed Mater Res A 2009, 88:437-447.
10. Májek P, Reicheltová Z, Satrnar J, Malý M, Oravec M, Pečančíková K, Dyr JE: Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1. J Transl Med 2011, 9:84.
11. Májek P, Reicheltová Z, Štárková J, Satrnar J, Sobottková A, Dyr JE: Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Sci 2010, 8:66.
12. Redel T, Satrnar J, Brynda E, Houska M, Medved L, Dyr JE: Fibrinopeptides A and B release in the process of surface fibrin formation. Blood 2011, 117:1700-1706.
13. Kay R, Barton C, Ratcliffe L, Matharoo-Ball R, Brown P, Roberts J, Teale P, Creaser C: Enrichment of low molecular weight serum proteins using acetoniitrile precipitation for mass spectrometry based proteomic analysis. Rapid Commun Mass Spectrom 2008, 22:3255-3260.
14. Lange V, Picotti P, Domon B, Aebersold R: Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4:222.
15. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Kripp S, Strupp C, Lazzarino M, Aul C, Cazzola M: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
16. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olthen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P: Differential expression of protease activities
confer tumor-specific serum peptide patterns. J Clin Invest 2006, 116:271–284.

17. Abdullah-Soheimi SS, Lim BK, Hashim OH, Shuib AS: Patients with ovarian carcinoma excrete different altered levels of urine CD59, kiningen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci 2010, 8:89.

18. Lewis JG, André CM: Effect of human alpha 2HS glycoprotein on mouse macrophage function. Immunology 1980, 39:317–322.

19. van Oss CJ, Gillman CF, Bronson PM, Border JR: Opsonic properties of human serum alpha-2 hs glycoprotein. Immunol Commun 1974, 3:329–335.

20. Ohnishi T, Arakaki N, Nakamura O, Hiroko S, Daikuhara Y: Purification, characterization, and studies on biosynthesis of a 59-kDa bone sialic acid-containing protein (BSP) from rat mandible using a monoclonal antibody. Evidence that 59-kDa BSP may be the rat counterpart of human alpha 2-HS glycoprotein and is synthesized by both hepatocytes and osteoblasts. J Biol Chem 1991, 266:14636–14645.

21. Yoshida Y, Takahashi Y, Yoshikawa T, Nomomura A, Yoshio A: Suppressive effect of alpha2 Heremans-Schmid glycoprotein on in vitro calcification of osteogenesis. Pediatr Int 2006, 48:11–16.

22. Lebreton JP, Josif E, Raoult JP, Lannuzel B, Roger JP, Humbert G: Serum concentration of human alpha 2 Hs glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979, 64:1118–1129.

23. Daveua M, Christian-Davinchke, Julen N, Hicon M, Arnaud P, Lebreton JP: The synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS 1988, 241:191–194.

24. Dziegielewsk KM, Brown WM, Gould CC, Matthews N, Sedgwick JE, Saunders NR: Fetuin: an acute phase protein in cattle. J Comp Physiol B 1992, 162:167–171.

25. Ren J, Davidoff AJ: Alpha2-Heremans Schmid glycoprotein, a putative inhibitor of tyrosine kinase, prevents glucose toxicity associated with cardiomyocyte dysfunction. Diabetes Metab Res Rev 2012, 28:305–310.

26. Kalabay L, Cseh K, Pajor A, Baranyi E, Csákány GM, Melczer Z, Speer G, Májek et al. Proteome Science 2010, 9:722.

27. Westenfelder R, Schäfer C, Krüger T, Haarmann C, Schurgers LJ, Reutelingsperger C, Ivanovski O, Drudeke T, Massy ZA, Ketteler M, Floege J: Increased unbound retinol-binding protein 4 concentration induces apoptosis through receptor-mediated signaling. J Biol Chem 2012, 287:9694–9707.

28. Tang XH, Gudas LJ: Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 2011, 6:345–364.

29. Bouchal P, Jarkovsky J, Hrazdilova K, Dvorakova M, Struharova I, Hernychova L, Damborsky J, Sova P, Vojtesek B: The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo. Proteome Sci 2011, 9:68.

with organ function, metabolism and inflammation. Crit Care 2010, 14:R179.

30. Cumová J, Jelíčková L, Potěšil D, Sedo O, Jezskal K, Potáčková A, Zdráhal Z, Mäjek R: Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens. Klin Onkol 2012, 25:17–25.

31. Lorkova L, Pospíšilova J, Lacheta J, Lehmahmschi S, Zivny J, Cibula D, Zivny J, Petrák J: Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics. Oncof Rev 2012, 27:318–324.

32. Chen OH, Hišel TJ, Lin KD, Lin HY, Lee MY, Hung WW, Hsiao PJ, Shin SJ: Increased unbound retinol-binding protein 4 concentration induces apoptosis through receptor-mediated signaling. J Biol Chem 2012, 287:9694–9707.

33. Zanotti G, Berni R: Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. Vitam Horm 2004, 64:271–295.

34. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T: Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007, 92:2712–2719.

35. Koch A, Weiskirchen R, Sansor E, Zimmermann HW, Voigt S, Dückers H, Trautwein C, Tack F: Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation Inclusion in PubMed, CAS, Scopus and Google Scholar

Immediat publication on acceptance

Convenient online submission

No space constraints or color figure charges

Submit your manuscript at bio medcentral.com/submit

Cite this article as: Mäjek et al.: Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. Proteome Science 2013 11:14